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Plants of the genus Valeriana (Valerianaceae) are used in traditional medicine as a mild sedative, antispasmodic and tranquilizer
in many countries. This study was undertaken to explore the neurobehavioral eﬀects of systemic administration of a valepotriate
extract fraction of known quantitative composition of Valeriana glechomifolia (endemic of southern Brazil) in mice. Adult animals
were treated with a single intraperitoneal injection of valepotriate fraction (VF) in the concentrations of 1, 3 or 10mgkg−1,o r
with vehicle in the pre-training period before each behavioral test. During the exploration of an open ﬁeld, mice treated with
10mgkg−1 ofVFshowedreducedlocomotionandexploratorybehavior.Althoughoverallhabituationsessionsforlocomotionand
exploratory behavior among vehicle control and doses of VF were not aﬀected, comparison between open-ﬁeld and habituation
sessions within each treatment showed that VF administration at 1 and 10mgkg−1 impaired habituation. In the elevated plus-
maze test, mice treated with VF (10mgkg−1) showed a signiﬁcant increase in the percentage of time spent in the open arms
withoutsigniﬁcanteﬀectsinthenumberoftotalarmentries.VFat3mgkg−1 producedanimpairmentofnovel-objectrecognition
memory. In contrast, VF did not aﬀect fear-related memory assessed in an inhibitory avoidance task. The results indicate that VF
can have sedative eﬀects and aﬀect behavioral parameters related to recognition memory.
1.Introduction
Complementary and alternative medicines (CAMs) have a
long history of use for the treatment of sleep disorders [1].
The species of Valeriana are known for medical properties
that date back to many centuries [2], and the herbal
supplement valerian (Valeriana oﬃcinalis) is one of the most
popular CAM therapies for insomnia [3, 4].
More than 100 constituents have been identiﬁed in
Valeriana sp., including sesqui and monoterpenes (hydro-
philic valerenic acids and the hydrophobic valepotriates,
resp.), which may account for the activity in the cen-
tral nervous system [2]. Valepotriates are iridoids with a
cyclopenta(c)pyranoid skeleton, an epoxy ring and three
ester linkages, without glycosidic linkages [5], and con-
troversial pharmacological activity [6]; their degradation
products, valtroxal, 8,9-didehydro-7-hydroxy-dolichodial,
11-ethoxyviburtinal and baldrinal may account for valerian’s
eﬀect [7]. Although several clinical studies revealed sleep-
improvement properties, there is no scientiﬁc agreement
on the sedating mode of action or the active constituents
responsible for the valerian eﬀects [2, 3, 8, 9].
Valeriana glechomifolia Meyer is an herb that grows in a
restrictedareaofsouthernBrazil,andisnotcurrentlyusedas
a phytomedicine. This plant accumulates valepotriates, both
in shoots (1.57g% DW) and roots (0.47g% DW) [10]. As
an alternative to the extraction of ﬁeld-grown plants of V.
glechomifolia for studies on pharmacological properties of2 Evidence-Based Complementary and Alternative Medicine
the species, we developed in vitro propagation protocols and
studiedthekineticsofgrowthandvalepotriateproductionin
aseptically cultivated plants [11–13].
Theactivityofvalepotriatesinthecentralnervoussystem
remains inconclusive and the pharmacological eﬀects of
V. glechomifolia have not been examined yet. Therefore,
a detailed behavioral and memory analysis of the eﬀect
of a valepotriate extract fraction of known quantitative
composition from this species was carried out in mice
model to evaluate locomotion (open ﬁeld), anxiety (elevated
plus maze), aversive memory (inhibitory avoidance) and
declarative memory (object recognition).
2. Methods
2.1. Plant Material. Valeriana glechomifolia Meyer plants
were collected in the region of Aparados da Serra, near
the city of S˜ ao Jose dos Ausentes (28◦44 54   south and
50◦03 57   west), state of Rio Grande do Sul, Brazil, in
the autumn. The species was identiﬁed by Dr M. Sobral
and a voucher specimen (Sobral, 7733) is deposited at the
Herbarium of the Federal University of Rio Grande do Sul
(ICN). The plants were frozen, lyophilized, powdered and
stored in freezer.
2.2. Preparation of Chloroform Extract of Valerian.
Lyophilized shoots and roots of the plant were crushed
to a particle size <850μm. Approximately 100g (dry weight)
was extracted twice with 500mL of chloroform for 15min
using a sonication bath (Ultrasonic). The extract was ﬁltered
through a glass ﬁlter and evaporated to dryness in vacuum
at 40◦C, yielding 4.21g of extract.
2.3. Preparation of Semi-Puriﬁed Valepotriate Fraction. To
further purify the valepotriate fraction (VF), the dried
extract was separated by silica gel vacuum column chro-
matographywithahexane:chloroformgradient.Thefraction
containing valepotriates was monitored by preparative thin-
layer chromatography (TLC) with chloroform:methanol
(50:0.5) as eluent [10]. The VF was concentrated and used
in the behavior tests.
2.4. Quantiﬁcation of Valepotriates. High-pressure liquid
chromatography (HPLC) analysis of valepotriates in the VF
was performed as previously described [10]. The VF (3 ×
5mg)wasdissolved in methanolandanalyzedinaShimadzu
equipment, using a Nova-Pack C18 column and pre-column
(Waters). The mobile phase was acetonitrile/water 50:50
(v/v), and the ﬂow rate 1mLmin−1; detection was done
at 208nm (didrovaltrate, retention time of 19.8min) and
254nm (acevaltrate, retention time of 18.1min and val-
trate, 34.8min) [10–14]. The valepotriates used as external
standards were isolated as described elsewhere [10] and the
identity and purity of the compounds were conﬁrmed by
nuclear magnetic resonance (1H NMR) [14]. The spectral
data were identical to those reported in the literature [15].
The phytochemical analysis revealed that the VF contained
96%ofvalepotriates(5mgofVFcontained2.05 ±0.11mgof
didrovaltrate, 1.66 ± 0.05mg of valtrate and 1.10 ± 0.01mg
of acevaltrate).
2.5. Animals. Swiss male CF1 mice (60–90 days old with
mean body weight of 36.18 ± 3.41g) obtained from the
State Foundation for Production and Research in Health
(FEPPS), Porto Alegre/Rio Grande do Sul/Brazil, were used
in the pharmacological assays. Each group consisted of 8–10
animals, kept on a 12h light/dark cycle with food and water
available ad libitum.B e h a v i o r a lp r o c e d u r e sw e r ec o n d u c t e d
between 11 a.m. and 6 p.m. Experimental procedures were
performed in accordance with the European Convention for
the Protection of Vertebrate Animals Used for Experimental
and Other Scientiﬁc Purposes (European Treaty Series—
No. 170 revised 2005) and the procedures of the Brazilian
College of Laboratory Animals (COBEA). The experimental
protocols were approved by the institutional research ethics
and animal care committee (document number GPPG-
HCPA 05–519). All eﬀorts were made to minimize the
number of animals and their suﬀering.
2.6. Drugs and Pharmacological Procedures. The VF was
suspended in saline with Tween-80, 5.0% (v/v). Fresh
solutions were prepared each time and intraperitoneally
injected in a volume of 10mLkg−1 body weight at the doses
of 1, 3 or 10mgkg−1; the control mice were injected with
vehicle. A well-established positive control of elevated plus
maze, diazepam intraperitoneal (i.p.) injection (1mgkg−1,
obtainedfromDEGImp.deProdutosQu´ ımicosLtda,Brazil)
was also examined in this task. VF injections were given
30min before the elevated plus maze and 30min before each
training of the behavioral test.
2.7. Open-Field Behavior. The open-ﬁeld exploration was
carriedoutaspreviouslydescribed[16].Theopenﬁeldwasa
50 ×25cmarena,surroundedby50cmhighwalls,andmade
of plywood with a frontal glass wall. The ﬂoor of the arena
was divided into 12 equal squares by black lines. Animals
wereplacedontheleftrearquadrantandlefttofreelyexplore
the arena for 5min. Latency to start locomotion, crossings
of the black lines, rearings performed and the number of
fecal pellets were counted. The numbers of crossings and
r e a r i n g sw e r eu s e da sm e a s u r e so fl o c o m o t o ra c t i v i t ya n d
exploratory behavior, respectively, whereas the latency to
start locomotion and the number of fecal pellets were used
as indicators of anxiety. After 24 hours, animals were left to
explore the apparatus again for another 5min, and the same
measures were recorded to evaluate habituation memory to
the open ﬁeld.
2.8. The Elevated Plus-Maze Test. The elevated plus maze
used in this study was modiﬁed from Lister [17]. The
apparatus, elevated 45 cm from the ﬂoor, consisted of two
open arms (30 × 6cm) opposite to one another and crossed
at right angles by two enclosed arms (30 × 6 × 15cm) with
an open roof. Anxiolytic compounds selectively increase the
percentage of time spent and/or arm entries in the open
arms;incontrast,anxiogeniccompoundsselectivelydecreaseEvidence-Based Complementary and Alternative Medicine 3
the percentage of time spent and/or arm entries in the open
arms. The number of entries and the total time spent in each
of the two arm types were taken during a 5-min test period
after the mice had been placed in the center of the maze
30min following VF, diazepam or vehicle administration.
2.9. Novel Object Recognition. The novel object recognition
task was performed as previously described [16]. Object
recognition training and test trials took place in the same
arena used for the open ﬁeld. After 24 hours of a 5-min
arena habituation session, the mice were trained in the novel
object recognition task. Training was conducted by placing
individual animals for 5min into the arena, in which two
identical objects (objects A1 and A2; Lego Duplo toys) were
positioned in two adjacent corners, 10cm from the walls.
In a long-term memory retention test given 24 hours after
training, the same mice explored the ﬁeld for 5min in the
presence of familiar object A1 and a novel object B. All
objects presented similar textures and sizes, but distinctive
colors and shapes. Exploration was deﬁned as sniﬃng or
touching the object with the nose and/or forepaws. The
exploratory preference was deﬁned as the percentage of the
total exploration time that the animal spent investigating
object A2 (in the training) or the novel object.
2.10. Inhibitory Avoidance. The step-down inhibitory avoid-
ance apparatus and procedures were described in previous
studies [16]. The inhibitory avoidance training box was a 50
× 25 × 25cm acrylic box whose ﬂoor consisted of parallel
stainless-steel bars. A platform (10 × 10 × 2cm) was placed
on the center of the ﬂoor. In the training trial, animals were
placed on the platform, and their latency to step-down on
the grid with all four paws was recorded. Immediately after
stepping down on the grid, animals were given a 0.6 mA/3s
footshock. In the retention test session carried out 24 hours
after training, no footshocks were given on test and a ceiling
of 180 s was imposed in the test latency.
2.11. Statistical Analysis. Open ﬁeld, habituation, elevated
plus maze and novel object recognition data were expressed
as mean ± standard error. Data for inhibitory avoidance
were expressed as median + interquartile range of step-
downlatencies.Comparisonsamonggroupswereperformed
using one-way analysis of variance (ANOVA) followed by
LSD (parametric data) or Kruskal-Wallis analysis of variance
followed by Mann-Whitney U (non-parametric data) tests
when necessary. Comparisons between behavioral trials
within the same group (comparisons between open-ﬁeld
behavior session and habituation session in the open-ﬁeld
test, comparisons between training and test sessions in the
novel object recognition and in the inhibitory avoidance)
weredonebyWilcoxontest.P-valuesof<.05wereconsidered
to indicate statistical signiﬁcance. Statistical analyses were
performed using the statistical software package SPSS.
3. Results
3.1. Open-Field Behavior and Open-Field Habituation. The
results showed that there were no signiﬁcant diﬀerences
among groups in the latency to start locomotion in open-
ﬁeld sessions (F(3,36) = 2.35, P = .09; Figure 1(a)), or
number of fecal pellets (F(3,36) = 1.65, P = .20; Figure 1(b)).
H o w e v e r ,m i c et r e a t e dw i t hV Fa t1 0 m g k g −1 showed
signiﬁcantly lower numbers of crossings (F(3,36) = 2.95, P
= .046; Figure 1(c)) and rearings (F(3,36) = 3.09, P = .039;
Figure 1(d)), which indicate alterations in locomotion and
reduced exploratory behavior, compared with the control
animals.
Results for open-ﬁeld habituation session, 24 hours
after the ﬁrst open-ﬁeld exploration session, are shown
in Figure 1. There were no signiﬁcant diﬀerences among
groups in the latency to start locomotion (F(3,36) = 1.57, P
= .21; Figure 1(a)), number of fecal pellets (F(3,36) = 2.32, P
= .09; Figure 1(b)), number of crossings (F(3,36) = 1.43, P
= .25; Figure 1(c)) or number of rearings (F(3,36) = 1.23, P
= .31; Figure 1(d)), indicating no alterations in locomotion
and reduced exploratory behavior in the habituation session,
compared with the control animals.
For addressing the habituation process of the open-ﬁeld
experiment (Figure 1)i nam o r es p e c i ﬁ cw a y ,W i l c o x o n
tests were applied between sessions of the same treatment.
These tests showed the expected signiﬁcant decrease in
the number of rearings during habituation session in the
control mice treated with vehicle (P = .008). This proﬁle
was maintained in mice that received 3mgkg−1 of VF
(P = .038). However, mice treated with 1mgkg−1 of VF
showed no diﬀerence in the rearings (P = .767), whereas
those treated with VF 10mgkg−1 (P = .037) displayed an
increased number of rearings during the habituation session,
indicatinganimpairmentinthehabituationprocess.Control
mice also showed the expected signiﬁcant decrease in the
latency to start locomotion (P = .036), a response that was
not observed in any of the VF concentrations. The highest
doses of VF (3 and 10mgkg−1)c a u s e dm i c et op r o d u c e
more fecal pellets (P = .035 and .039, resp.), indicating
increased anxiety in the habituation session (24 hours after
VF administration).
3.2. The Elevated Plus-Maze Test. Mice treated with
10mgkg−1 VFordiazepamat1mgkg−1 showedasigniﬁcant
increase in the percentage of time spent in the open arms
when compared with control mice (F(3,36) = 2.729, P = .032
and .014, resp.; Figure 2). In addition, animals treated with
diazepam also showed increased total number of arm entries
(F(3,36) = 5.31, P = .001), whereas the VF treatments did
not aﬀect this exploratory behavior signiﬁcantly (VF 1, 3 and
10mgkg−1; P = .219, .818 and .235, resp.). There was no
signiﬁcant diﬀerence among VF treatments in the number
of open-arms entries on the elevated plus-maze test (F(3,36)
= 0.315, P = .814).
3.3. Novel Object Recognition. Results for the eﬀects of the
VF administration on memory assessed in the novel object
recognition task are shown in Figure 3. There were no
diﬀerences among groups in the total time spent exploring
both objects during training (F(3,36) = 1.61, P = .21),
indicating that all groups showed similar locomotion and4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Open-ﬁeld behavior and habituation in mice treated with a systemic administration of VF (1, 3 or 10mgkg−1)o fV. glechomifolia
30min before the ﬁrst open-ﬁeld exploration session. Animals were left to freely explore the arena for 5min day−1 during 2 days. Data are
mean ± SEM. (a) Latency to start locomotion (s), (b) number of fecal pellets, (c) number of crossings and (d) number of rearings. n = 10
animals per group. ∗P<. 05, signiﬁcant diﬀerence from the control group.
motivation during task acquisition. Mean ± SE total explo-
ration time (s) was 80.9 ± 7.2 (control), 87.4 ± 7.9 (VF,
1mgkg −1), 63.3 ± 7.8 (VF, 3mgkg−1), and 70.6 ± 11.2 (VF,
10mgkg−1). There was no signiﬁcant diﬀerence between
groupsinexploratorypreferenceinthetrainingtrial(F(3,36)
= 1.30, P = .29). Moreover, there was a signiﬁcant diﬀerence
among groups in exploratory preference during test (F(3,36)
= 4.37, P = .01). Further analysis revealed a signiﬁcant
diﬀerence between the control group and the group given
VF at 3mgkg−1 in long-term recognition memory retention
tested 24 hours after training (P = .008). These ﬁndings
indicatethatpretrainingsystemicadministrationofVFatthe
dose of 3mgkg−1 produced an impairment of novel object
recognition memory.
Wilcoxon tests showed a signiﬁcantly higher novel object
exploratory preference in the VF at dose of 10mgkg−1 (P
= .017). The vehicle and VF 1mgkg−1 treated group fell
short of signiﬁcance (P = .069 and .066, resp.) and there
was no signiﬁcant diﬀerence among training and test at VF
3mgkg −1-treated group (P = .515).
3.4. Inhibitory Avoidance. Results for inhibitory avoidance
are shown in Figure 4. In all groups, there were signiﬁcant
training-test diﬀerences (Wilcoxon test, P < .05). There
were no signiﬁcant diﬀerences among groups in step-down
latencies in the training trial (H = 1.34, df = 3, P = .72; mean
± SEM overall training trial step-down latencies was 14.69
± 1.65s). In addition, there was no signiﬁcant diﬀerence
b e t w e e ng r o u p si nl o n g - t e r mm e m o r yr e t e n t i o nc a r r i e do u t
24haftertrainingwhencomparedwiththecontrolgroup(H
= 0.13, df = 3, P = .99). The results indicate that VF did not
aﬀect inhibitory avoidance memory.
4. Discussion
Valeriana sp. contain several compounds including essential
oils, terpenoids and small amounts of ﬂavonoids, alkaloids
and minerals [2, 5, 6]. Previous studies have reported the
eﬀect of higher polarity extracts (such as hydroalcoholic
extracts) on the central nervous system [4, 6]. Studies with
non-humans tend to support valerian as a central nervous
system depressant [18]. Neurobiological mechanisms have
been postulated to mediate its sedative and hypnotic eﬀects,
including binding studies for gamma-amino butyric acid
(GABA) [18, 19], serotononergic [8, 20], dopaminergic and
noradrenergic [18] and A1 adenosine [18, 21]r e c e p t o r s
eﬀects.
Although valerian is used traditionally as a mild sedative,
research is sparse, and studies diﬀer greatly with respect to
design, measures and preparations used [22]. The role ofEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Elevated plus-maze behavior in mice treated with
a systemic administration of VF (1, 3 or 10mgkg−1)o fV.
glechomifolia 30min before behavioral testing. Animals were left
to freely explore the apparatus for 5min. The following parameter
is shown: percentage open-arm time (percentage of time spent in
open arms with respect to total time spent in the arms). Data are
mean ± SEM. n = 10 animals per group. ∗P<. 05, signiﬁcant
diﬀerence from the control group.
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Figure 3: Novel object recognition memory in mice treated
with a systemic administration of VF (1, 3 or 10mgkg−1)o fV.
glechomifolia 30min before the training. Memory retention was
tested 24 hours after training. Data are mean ± SEM exploratory
preferences during training (light columns) or test (dark columns)
trials. Exploratory preference was deﬁned as percentage time
exploring object A2 during training or percentage time exploring
the novel object B during test trials. n = 8 animals per group.
∗∗P<. 01, signiﬁcant diﬀerence from the control group.
valepotriates is considered somewhat controversial [6]. In
this study, the extract containing 96% of valepotriates of V.
glechomifoliaat10mgkg−1 waseﬀectiveinreducinglocomo-
tion and exploratory behavior during open-ﬁeld exploration
in mice, which is indicative of sedative properties. This con-
centration also increased the time spent on the open arms,
an indicative of anxiolytic property in the elevated plus-
maze test, a well-established rodent model of anxiety [23].
However, unlike diazepam (1mgkg−1), VF (10mgkg−1) did
not alter open-arm entries and total arm entries, but aﬀected
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Figure 4: Fear-related memory assessed in an inhibitory avoidance
task in mice treated with a systemic administration of VF (1, 3
or 10mgkg−1)o fV. glechomifolia 30min before training. Memory
retention was tested 24 h after training. Data are median +
interquartile range. Latencies to step-down (s) of training (light
columns) or test (dark columns). n = 9 animals per group. There
were no signiﬁcant diﬀerences among groups, either in the training
trial or in the test. Asterisks indicate groups showing signiﬁcant
training-test diﬀerences (Wilcoxon test, P < .05).
the time in closed arms. The eﬀect is dose dependent, with
lower doses of VF having no inﬂuence. Moreover, this dose
did not aﬀect the memory tests, compared with control
animals. One possible interpretation for the lack of eﬀect
of VF 10mgkg−1 on the number of arm entries is partial
locomotionimpairmentasobservedinFigure 1(c).However ,
low doses of diazepam are known to induce increase in
l o c o m o t i o na n dn u m b e ro fa r me n t r i e s[ 23, 24], which may
also have contributed to this result.
Neither object exploration during training in a novel
object recognition task nor inhibitory avoidance perfor-
mance was aﬀected by VF, whereas 24h retention of
recognition memory was impaired by a lower dose of VF
that did not aﬀect locomotion or exploration. Thus, a lower
dose of VF can selectively aﬀect formation of recognition
memorywithoutinducingovertnon-speciﬁceﬀectsonother
behavioral parameters.
It is interesting to note that the VF eﬀect that impaired
novel object recognition memory at the dose of 3mgkg−1
was not observed at the lower 1mgkg−1 and higher
10mgkg−1 doses. Previous studies evaluating the eﬀects of
injections of both memory enhancing [25] and memory
impairing [26] drugs on memory show that several treat-
ments produce an inverted-U dose-response curve [27].
This is the ﬁrst study, to our knowledge, that shows
the neuropharmacological proﬁle of an enriched VF from
V. glechomifolia, and the eﬀect of this valepotriate extract
in memory. Obviously, a crude extract may have diﬀerent
activity due to the presence of additional compounds
and interactions, which was not evaluated in the present
work because the focus was on valepotriates, the major6 Evidence-Based Complementary and Alternative Medicine
phytochemical components in this species. In addition,
valerian-based herbal medicines are usually taken orally,
an intake route through which valepotriates are poorly
absorbed, even though some of their catabolites, such
as baldrinal, may remain available [7]. I.p. injections as
employed in the present study may considerably change
bioavailability compared with oral intake, which may aﬀect
the observed activity. However, i.p. injections were used
to provide homogeneous applications and to maximize
bioavailability of valepotriates, the phytochemicals evaluated
in this ﬁrst investigation of pharmacological properties of V.
glechomifolia.
In summary, the present study indicates that systemic
administration of VF from V. glechomifolia has sedative
propertiesandcaninducealterationsinrecognitionmemory
and in the elevated plus-maze behavior in mice. Further
research is required to examine the neurochemical mecha-
nisms involved in the behavioral eﬀects.
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